Gilead Sciences Announces Second Quarter 2013 Financial Results DailyFinance Results from a Phase 2 study (Study 101-08) evaluating idelalisib (formerly GS-1101) in combination with rituximab for older patients with treatment-naïve chronic lymphocytic leukemia. This regimen achieved a complete response rate of 19 percent and an ... Gilead Sciences, Inc. (GILD) CEO Discusses Q2 2013 Results - Earnings Call ... |
